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Abstract
Objective
To determine whether early and more frequent mobilization after stroke affects health-related
quality of life.
Methods
AVery Early Rehabilitation Trial (AVERT) was an international, multicenter (56 sites), phase 3
randomized controlled trial, spanning 2006–2015. People were included if they were aged ≥18
years, presented within 24 hours of a first or recurrent stroke (ischemic or hemorrhagic), and
satisfied preordained physiologic criteria. Participants were randomized to usual care alone or
very early and more frequent mobilization in addition to usual care. Quality of life at 12 months
was a prespecified secondary outcome, evaluated using the Assessment of Quality of Life 4D
(AQoL-4D). This utility-weighted scale has scores ranging from −0.04 (worse than death) to 1
(perfect health). Participants who died were assigned an AQoL-4D score of 0.
Results
No significant difference in quality of life at 12 months between intervention (median 0.47,
interquartile range [IQR] 0.07–0.81) and usual care (median 0.49, IQR 0.08–0.81) groups was
identified (p = 0.86), nor were there any group differences across the 4 AQoL-4D domains. The
same lack of group difference in quality of life was observed at 3months.When cohort data were
analyzed (both groups together), quality of life was strongly associated with acute length of stay,
independence in activities of daily living, cognitive function, depressive symptoms, and anxiety
symptoms (all p < 0.001). Quality of life in AVERT participants was substantially lower than
population norms, and the gap increased with age.
Conclusions
Earlier and more frequent mobilization after stroke did not influence quality of life.
Clinical trial registration
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Classification of evidence
This study provides Class II evidence that for people with stroke, earlier and more frequent
mobilization did not influence quality of life over the subsequent year.
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Stroke can have a major effect on quality of life (QOL),1
a multidimensional construct that incorporates physical,
psychological, and social elements of well-being. The com-
prehensive scope of QOL means it has been viewed as the
single health outcome that is most relevant to the individual,2
and thus it is important to identify interventions that improve
QOL following stroke. Care in a stroke unit is one such in-
tervention.3 A component of stroke unit care that may con-
tribute to better outcomes is earlier mobilization, as this has
been independently associated with discharge to home within
6 weeks.4 More directly, our phase 2 trial indicated that early
and more frequent mobilization after stroke is associated with
benefit in the “Independent Living” domain of the Assess-
ment of Quality of Life 4D (AQoL-4D) instrument.5 Early
initiation of physical rehabilitation following stroke (within 7
days) has also been associated with better subsequent QOL.6
As a multidimensional construct, QOL has a diverse array of
contributing factors. Studies indicate that lower QOL after
stroke is strongly related to lack of functional independence,
depression, and older age.7,8 Cognitive impairment, too, has
been widely linked to low QOL after stroke.9,10 The delete-
rious effect of stroke on QOL has been reported in both
younger11 and older12 cohorts, but the important contributing
factors may differ across the lifespan. In younger people with
stroke, a reduced ability to concentrate was associated with
lower QOL.13 Even minor stroke-related deficits can have
a marked effect on QOL at this age: in a group of working-age
survivors of mild stroke, the majority reported limitations in
returning to leisure activities (58%) and work (52%).14 Given
that an individual judges QOL in his or her own unique
context, and in relation to goals and expectations, the effect of
stroke may also differ according to seemingly tangential fac-
tors such as geographic region or education background.
Methods
Study design
A Very Early Rehabilitation Trial (AVERT) phase 3 was
a pragmatic, parallel-group, single-blind, multicenter, ran-
domized controlled trial with blinded assessment of outcome,
conducted at 56 sites internationally.15 It was designed to
investigate the efficacy of very early mobilization (earlier and
more frequent out-of-bed activity), compared with usual care,
in acute stroke. The primary outcome was good functional
outcome (0–2 on the modified Rankin Scale [mRS]16) at 3
months. A prespecified secondary hypothesis—constituting
Class II evidence—was better QOL at 12 months in the in-
tervention than usual care group. The later time point was
chosen to reflect longer-term recovery and adjustment. Given
AVERT’s large sample size, we also planned to determine
associations between a range of demographic and clinical
factors and QOL in the full cohort (both groups together).
The trial had ethical approval from the relevant Human Ethics
Committee at each participating site. It was stopped when the
recruitment target of 2,104 was reached. Details of the study
rationale, design, and statistical analysis have been published
previously.17
Participants
Eligible participants were aged 18 years or older and were
recruited within 24 hours of a confirmed stroke (first or re-
current, ischemic or hemorrhagic). Exclusion criteria included
premorbid disability, early deterioration, palliation, other se-
rious illness or coronary condition, and physiologic readings
(blood pressure, heart rate, temperature) falling outside set
limits.
Randomization
Participants were randomly assigned to receive usual stroke
unit care alone or very early and more frequent mobilization
in addition to usual care, stratified by hospital site and stroke
severity. The randomization schedule was computer-
generated, with allocation concealed and delivered via a se-
cure, purpose-built online interface.
Intervention
For both intervention and control participants, the compo-
nents of usual care were at the discretion of individual sites.
The very early mobilization intervention comprised 3 crucial
elements: (1) begin within 24 hours of stroke onset, (2) focus
on out-of-bed activity (e.g., sitting, standing, walking), and (3)
result in at least 3 out-of-bed sessions per day in addition to
usual care. The intervention period lasted 14 days or until
discharge from the acute stroke unit, whichever was sooner.
Outcomes
The focus of the current analysis is the secondary outcome of
QOL at 12 months. The AQoL is a multiple-domain, utility-
weighted measure of health-related QOL.18 We used the
AQoL-4D, which has 12 items that cover 4 domains: In-
dependent Living (self-care, household tasks, mobility), So-
cial Relationships (relationships with others, social isolation,
family role), Physical Senses (seeing, hearing, communica-
tion), and Psychological Well-being (sleep, anxiety and de-
pression, pain). It also includes 3 items on Illness (prescribed
medicines, medication and aids, medical treatment), but these
do not contribute to the total AQoL-4D score. Each item has
4 response options, and the respondent is instructed to
Glossary
AQoL-4D = Assessment of Quality of Life 4D; AVERT = A Very Early Rehabilitation Trial; CI = confidence interval; IDA =
Irritability, Depression and Anxiety; IQR = interquartile range; MoCA = Montreal Cognitive Assessment; mRS = modified
Rankin Scale; NIHSS = NIH Stroke Scale; QOL = quality of life.
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choose the alternative that best describes him or her over the
last week. Raw scores are transformed into domain disutility
scores using specific algorithms that are based on weights
from an Australian population sample. Domain scores can
then be calculated using 1 − domain disutility score. Each
weighted domain score is between 0 (worst health state) to 1
(best health state). A single weighted overall utility score is
calculated from the 4 domain scores, and ranges from −0.04
(worse than death) to 0 (equivalent to death) to 1 (full
health). Blinded assessors administered the AQoL-4D at 3
and 12 months poststroke. Participants who had died were
assigned an AQoL-4D score of 0. In cases where the partici-
pant was unable to respond, responses from proxies (relative
or carer of the participant) were accepted. For participants
with verbal or written communication difficulties, a modified,
aphasia-friendly version was developed. Modifications in-
cluded large print (16-point font), bolded key words for each
question, and double paragraph spacing. Questions were
presented to participants one at a time with a point response.
For these participants, a proxy also completed the AQoL-4D.
Demographic details collected included age, sex, education,
marital status, living arrangements (institution was defined as
nursing home or other supported accommodation), em-
ployment status, premorbid physical disability (mRS), and
geographic region. Stroke characteristics included stroke se-
verity (using the NIH Stroke Scale [NIHSS]19), stroke sub-
type (using the Oxfordshire Community Stroke Project
classification20), and length of stay in the acute hospital.
Clinical outcome measures included the Irritability, De-
pression and Anxiety (IDA) scale,21 the Montreal Cognitive
Assessment (MoCA),22 and the Barthel index.23
Statistical analysis
The full statistical analysis plan for AVERT was published
prior to trial completion and database lock.17 We used
bootstrapped median regression to analyze between-group
differences in AQoL-4D at 12 months, adjusting for age, sex,
and stroke severity. This analytic approach was then applied
to each of the AQoL-4D domains. We then repeated the same
series of multivariable, bootstrapped median regression
analyses to determine whether there were any group differ-
ences in AQoL-4D at 3 months. Next we considered the
cohort as a whole, with intervention and usual care groups
together. Descriptive statistics were used to compare AQoL-
4D scores in the AVERT cohort to population norms24 across
the age range. To evaluate whether minor stroke-related
symptoms have a relatively greater effect on QOL in younger
people, we compared AQoL-4D scores in AVERT partic-
ipants with a 12-months mRS score of 1 or 2 to the population
norms. Bootstrapped median regression analyses, adjusted for
age, sex, and stroke severity, were employed to determine the
associations between QOL and stroke type, acute length of
stay, independence in activities of daily living, cognitive
function, depressive symptoms, and anxiety symptoms. Cor-
relations were computed to identify whether change in QOL
from 3 to 12 months was associated with change in mood
symptoms over this same period. Descriptive statistics were
used to outline differences in QOL between participants with
varying severity of aphasia, as classified by the NIHSS. Further
bootstrapped median regression analyses, adjusted for age,
sex, and stroke severity, were employed to determine the
associations between QOL and return to work, living
arrangements, geographic region, and education. All analyses
were performed using STATA version 14.0.
Data availability
Anonymized data not published within this article will be
made available by request from any qualified investigator.
Results
Mean age of the participants was 70.6 years (SD 12.8) and
61% were male. Characteristics of participants were similar
between groups (table 1). Among 2,104 participants, AQoL-
4D data at 12 months were available for 2,017 (96%), in-
cluding the 257 participants who had died and were assigned
a score of 0. Of the other 87, 28 (1%) refused follow-up, 24
(1%) were lost to follow-up, and 35 (2%) had missing data for
one or more AQoL-4D items (figure 1). There was little
evidence of attrition bias: the complete data group (n = 1,760)
were 62% male and had a median baseline NIHSS of 6 (IQR
4–11), whereas the missing data group (n = 87) were 61%
male and had a median baseline NIHSS of 6 (interquartile
range [IQR] 3–9). Interestingly, the missing data group
(mean age 65.3, SD 13.8) was younger than the complete data
group (mean age 69.9, SD 12.8) (t[93] = 3.0, p = 0.003).
At 12 months, AQoL-4D scores were similar in the in-
tervention (n = 1,002; median 0.47, IQR 0.07–0.81; mean
0.46, SD 0.37) and usual care (n = 1,015; median 0.49, IQR
0.08–0.81; mean 0.47, SD 0.36) groups. The distribution of
AQoL-4D scores is illustrated in figure 2. Adjusted median
regression indicated no significant group difference in either
total AQoL-4D scores (coefficient = −0.004; 95% confidence
interval [CI] −0.043, 0.036; p = 0.86) or in any of the 4
domains at 12 months: Independent Living (coefficient =
−0.007; 95% CI −0.038, 0.024; p = 0.66), Social Relationships
(coefficient = 0.011; 95%CI −0.007, 0.030; p = 0.24), Physical
Senses (coefficient = 0.009; 95% CI −0.004, 0.023; p = 0.16),
and Psychological Well-being (coefficient = 0.001; 95% CI
−0.011, 0.014; p = 0.85).
At 3 months, AQoL-4D was similar between the intervention
(n = 1,012; median 0.42, IQR 0.08–0.77; mean 0.44, SD 0.36)
and usual care (n = 1,019; median 0.44, IQR 0.09–0.77; mean
0.45, SD 0.35) groups, with no significant group difference on
median regression (coefficient = −0.019; 95% CI −0.058,
0.019; p = 0.33). Intervention participants scored higher than
usual care participants on the Physical Senses domain at 3
months (coefficient = 0.013; 95% CI 0.001, 0.025; p = 0.035),
but there were no group differences in the other 3 AQoL-4D
domains: Independent Living (coefficient = −0.026; 95% CI
−0.064, 0.011; p = 0.17), Social Relationships (coefficient =
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0.005; 95% CI −0.012, 0.023; p = 0.54), and Psychological
Well-being (coefficient = −0.003; 95% CI −0.013, 0.007;
p = 0.60).
Deaths excluded
When we included only surviving participants, bootstrapped
median regression analysis failed to detect a significant dif-
ference between groups at 12 months; AQoL-4D was similar
in intervention (n = 863; median 0.56, IQR 0.20–0.86; mean
0.53, SD 0.34) and usual care (n = 897; median 0.56, IQR
0.22–0.86; mean 0.53, SD 0.34). The group comparison was
little changed when the sample was further restricted to sur-
vivors who had not experienced a serious adverse event of
stroke progression or recurrent stroke over the 12 months of
follow-up; AQoL-4D at 12 months was similar in intervention
(n = 798; median 0.58, IQR 0.25–0.87; mean 0.55, SD 0.34)
and usual care (n = 835; median 0.57, IQR 0.25–0.87; mean
0.55, SD 0.34). In all survivors at 3 months, AQoL-4D was
similar in the intervention (n = 924; median 0.48, IQR
0.16–0.81; mean 0.48, SD 0.34) and usual care (n = 947;
median 0.50, IQR 0.17–0.80; mean 0.49, SD 0.34) groups.
Mean change in AQoL-4D between 3 and 12months revealed
comparable improvement across time in intervention (n =
852, mean 0.03, SD 0.22) and usual care (n = 885, mean 0.02,
SD 0.21) groups. In the intervention group, QOL improved
between 3 and 12 months in 53% of participants, declined in
38%, and was unchanged in 9%; in usual care, it improved in
51%, declined in 40%, and was unchanged in 9%.
Intervention and usual care groups combined
With participants grouped into age decades, we observed an
inverse relationship between age and QOL (figure 3). QOL
was lower in our stroke sample than in population norms,24
and this difference increased as age increased (table 2). When
excluding the smaller samples of participants under 40 years
old, the difference in median AQoL-4D score between our
participants and the norms grew with each decade of life: 0.15
in the 40s, 0.20 in the 50s, 0.25 in the 60s, 0.30 in the 70s, and
0.43 in the over-80s. When comparing AQoL-4D scores of
those with a 12-month mRS score of 1 or 2 to the population
norms, we observed the opposite pattern, with the difference
in medians decreasing as age increased: 0.15 in the 50s, 0.14 in
the 60s, 0.11 in the 70s, and 0.07 in the over-80s (table 2).
Association with clinical variables
No significant difference in AQoL-4D was identified between
participants with ischemic and hemorrhagic stroke, at either 3
or 12months (table 3). Higher AQoL-4D scores at both 3 and
12 months were significantly associated with shorter acute
length of stay, greater independence in activities of daily living
(Barthel Index at 3 months), better cognitive function
(MoCA at 3 months), and fewer depressive and anxiety
symptoms (IDA subscales at 3 months). Change in AQoL-4D
score between 3 and 12 months was significantly correlated
with change in depressive (n = 1,555; r = −0.32, p < 0.001)
and anxiety (n = 1,551; r = −0.29, p < 0.001) symptoms over
the same time period. Participants identified as having aphasia
(as per the NIHSS item) had lower AQoL-4D scores at 12
months than those without aphasia (table 4).
Association with demographic factors
There were 527 participants who were employed at the time
of their stroke. At both 3 and 12 months, those who had
returned to work had better QOL than those who had not
returned (table 3). Participants living in an institution at
Table 1 Characteristics of the 2,104 A Very Early
Rehabilitation Trial (AVERT) participants
Intervention Usual care
N 1,054 1,050
Sex, female 411 (39) 407 (39)
Age, mean years (SD) 70.3 (13.0) 70.9 (12.6)
NIHSS, median (IQR) 7 (4–12) 7 (4–12)
Mild (1–7) 592 (56) 578 (55)
Moderate (8–16) 315 (30) 328 (31)
Severe (>16) 147 (14) 144 (14)
OCSP
TACI 224 (21) 232 (22)
PACI 340 (32) 328 (31)
POCI 93 (9) 106 (10)
LACI 255 (24) 268 (26)
Haemorrhage 142 (14) 116 (11)
Premorbid mRS
0 799 (76) 786 (75)
1 145 (14) 158 (15)
2 110 (10) 106 (10)
Previous psychiatric history 85 (8) 74 (7)
Married or de facto 724 (69) 713 (68)
Education
University 113 (11) 105 (11)
Trade/diploma 295 (29) 290 (29)
Finished HS 292 (29) 283 (28)
Did not finish HS 304 (30) 315 (32)
Region
Australia/New Zealand 617 (59) 626 (60)
Asia 126 (12%) 125 (12%)
United Kingdom 311 (30%) 299 (28%)
Abbreviations: HS = high school; LACI = lacunar infarct; mRS = modified
Rankin Scale; NIHSS = NIH Stroke Scale; OCSP = Oxfordshire Stroke Classi-
fication; PACI = partial anterior circulation infarct; POCI = posterior circula-
tion infarct; TACI = total anterior circulation infarct.
Values are n (%), mean (SD), or median (interquartile range).
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3 months (n = 130) and at 12 months (n = 148) had lower
QOL than those not living in an institution at these time
points. Splitting participants by geographic region, AQoL-4D
at 3 months was highest in Asia (median 0.58, IQR
0.20–0.85), followed by Australia/New Zealand (median
0.50, IQR 0.16–0.79) and the United Kingdom (median 0.42,
IQR 0.13–0.79). The same pattern was identified at 12
months: Asia (median 0.72, IQR 0.28–0.94), Australia/New
Figure 1 CONSORT flowchart
AQoL = Assessment of Quality of Life;
AVERT = A Very Early Rehabilitation
Trial.
Figure 2 Distribution of Assessment of Quality of Life 4D (AQoL-4D) scores at 12 months in intervention and usual care
groups
<0 Is considered “worse than death,” 0 was
assigned to participants who had died, 1 is
considered perfect health.
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Zealand (median 0.57, IQR 0.23–0.84), and the United
Kingdom (median 0.49, IQR 0.14–0.83). Compared to
Australia/New Zealand, AQoL-4D was significantly lower in
the United Kingdom at both time points (table 3). In terms of
education, AQoL-4D at 3 months was highest in those with
a university degree (median 0.60, IQR 0.23–0.84), followed
by those with a trade or diploma (median 0.54, IQR
0.22–0.84), then those who finished high school (median
0.48, IQR 0.16–0.81), and those who did not complete high
school (median 0.40, IQR 0.11–0.73). The same pattern was
identified at 12 months: university degree (median 0.68, IQR
0.30–0.91), trade or diploma (median 0.61, IQR 0.23–0.88),
finished high school (median 0.56, IQR 0.24–0.86), did not
complete high school (median 0.51, IQR 0.16–0.79). Com-
pared to people not finishing high school, QOL was signifi-
cantly higher in all 3 other education groups at both 3 and 12
months (table 3).
Proxy respondents
QOL at 3 months was poorer for participants with a proxy
respondent (n = 207; median 0.05, IQR −0.01 to 0.24) than
for participants who responded themselves (n = 1,664; median
0.56, IQR 0.23–0.83). Similarly, 12-month QOL was poorer for
those with a proxy respondent (n = 220; median 0.07, IQR
0.00–0.30) than for those who responded themselves (n = 1,540;
median 0.63, IQR 0.30–0.89). Our aphasia-friendly version of the
AQoL-4D was designed to increase the chance of participants
with communication difficulties responding themselves, but it was
used in only 14 participants. Given such low numbers, proxy data
were used for these respondents.
Discussion
AVERT included a very large cohort of stroke survivors,
recruited across 56 hospital sites internationally. This,
Table 2 Grouped by age decade, Assessment of Quality of Life 4D scores from (1) published population norms,24 (2) all
surviving A Very Early Rehabilitation Trial (AVERT) participants at 12 months poststroke, and (3) AVERT
participants with minor symptoms (modified Rankin Scale [mRS] 1 or 2) at 12 months poststroke
Age
Population norms AVERT survivors at 12 months AVERT mRS 1–2 at 12 months
N Median (IQR) N Median (IQR) N Median (IQR)
≤29 1,325 0.93 (0.80–1.00) 10 0.99 (0.59–1.00) 4 0.95 (0.66–0.99)
30–39 1,681 0.91 (0.77–1.00) 27 0.70 (0.35–0.98) 15 0.69 (0.34–1.00)
40–49 1,382 0.89 (0.76–1.00) 102 0.74 (0.39–0.93) 57 0.86 (0.63–0.98)
50–59 1,295 0.89 (0.73–1.00) 229 0.69 (0.38–0.93) 126 0.74 (0.56–0.93)
60–69 1,245 0.89 (0.73–1.00) 435 0.64 (0.33–0.90) 222 0.75 (0.55–0.91)
70–79 912 0.85 (0.73–0.96) 546 0.55 (0.18–0.84) 237 0.74 (0.55–0.89)
≥80 357 0.77 (0.58–0.95) 411 0.34 (0.08–0.68) 120 0.70 (0.50–0.85)
Abbreviation: IQR = interquartile range.
Figure 3 Boxplots of Assessment of Quality of Life 4D (AQoL-4D) scores at 12 months in all surviving A Very Early
Rehabilitation Trial (AVERT) participants, grouped by age decade
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combined with the wide inclusion criteria, meant the sam-
ple was broadly representative of the general stroke pop-
ulation. QOL data were collected over the year following
stroke, with very low rates of missing data and loss to
follow-up. Our hypothesis that the intervention group
would have better overall QOL than the usual care group at
12 months poststroke was not supported. Furthermore,
there was no group difference in any of the 4 AQoL-4D
domains at 12 months. Similarly, group comparison of total
AQoL-4D score at 3 months yielded no significant differ-
ence. The only significant group difference in domain score
at 3 months was in Physical Senses, where intervention
participants had better QOL than usual care participants.
While statistically significant, however, this difference was
not clinically meaningful and was confined to the lower end
of the distribution (both groups had a median utility score
of 0.94 for the Physical Senses domain). The tendency
towards better scores on the Independent Living domain
identified in the intervention arm of AVERT phase 25 was
not replicated here.
The lack of group difference in QOL contrasts with AVERT’s
primary outcome analysis, which indicated that fewer in-
tervention participants had a favorable functional outcome at
3 months (mRS 0–2) than controls (46% vs 50%, adjusted
odds ratio 0.73 [95% CI 0.59–0.90], p = 0.004).15 While an
association between mRS outcome and QOL after stroke has
been demonstrated,25 the strength of correspondence is di-
luted by substantial variability. At 3 months poststroke, QOL
at a given mRS level is highly heterogeneous.26 Such findings
Table 3 Associations between quality of life and clinical and demographic variables; separate bootstrapped median
regressions, each one adjusted for age, sex, and stroke severity
AQoL-4D 3 months AQoL-4D 12 months
Coefficient 95% CI p Value Coefficient 95% CI p Value
Stroke type −0.026 −0.082, 0.030 0.36 −0.007 −0.073, 0.060 0.84
Acute LOS −0.004 −0.005, −0.004 <0.001 −0.004 −0.006, −0.003 <0.001
Barthel 3 months 0.036 0.034, 0.039 <0.001 0.034 0.032, 0.037 <0.001
MoCA 3 months 0.015 0.010, 0.020 <0.001 0.019 0.013, 0.026 <0.001
IDA depression 3 months −0.062 −0.068, −0.056 <0.001 −0.067 −0.072, −0.062 <0.001
IDA anxiety 3 months −0.058 −0.063, −0.054 <0.001 −0.064 −0.072, −0.058 <0.001
Return to work 3 months 0.206 0.131, 0.282 <0.001
Return to work 12 months 0.220 0.134, 0.306 <0.001
Institution 3 months −0.180 −0.224, −0.135 <0.001
Institution 12 months −0.292 −0.349, −0.235 <0.001
UK (vs Australia/New Zealand) −0.054 −0.089, −0.019 0.003 −0.058 −0.105, −0.010 0.018
Asia (vs Australia/New Zealand) −0.045 −0.137, 0.046 0.33 0.018 0.053, 0.089 0.62
Finished HS (vs incomplete HS) 0.053 0.003, 0.103 0.037 0.071 0.021, 0.120 0.005
Trade/diploma (vs incomplete HS) 0.096 0.050, 0.142 <0.001 0.078 0.027, 0.128 0.002
University (vs incomplete HS) 0.084 0.013, 0.156 0.021 0.089 0.023, 0.154 0.008
Abbreviations: AQoL-4D = Assessment of Quality of Life 4D; CI = confidence interval; HS = high school; IDA = Irritability, Depression and Anxiety scale; LOS =
length of stay; MoCA = Montreal Cognitive Assessment; UK = United Kingdom.
Table 4 Total Assessment of Quality of Life 4D (AQoL-4D)
scores at 12 months in surviving participants
according to language status on the NIH Stroke
Scale (NIHSS) at baseline and 3 months
N
AQoL 12 months,
median (IQR)
Baseline NIHSS language
No deficit 1,216 0.62 (0.29, 0.89)
Mild–moderate aphasia 310 0.53 (0.17, 0.79)
Severe aphasia 184 0.34 (0.07, 0.74)
No speech or understanding 50 0.09 (−0.01, 0.33)
3-month NIHSS language
No deficit 1,119 0.63 (0.30, 0.89)
Mild–moderate aphasia 196 0.44 (0.07, 0.71)
Severe aphasia 79 0.07 (−0.01, 0.23)
No speech or understanding 7 −0.01 (−0.02, 0.02)
Abbreviation: IQR = interquartile range.
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have prompted attempts to develop a utility-weighted
mRS,27,28 with the aim to reflect patient perception of QOL
and thus enhance interpretability of the ordinal scale. It is
possible that the AVERT intervention may have improved
some aspects of QOL that are reflected in the AQoL-4D but
not in the mRS.
When the 2 groups were considered together, QOL in the
full AVERT cohort was substantially lower than pop-
ulation norms,24 giving support to previous findings of
lower QOL in stroke survivors than in stroke-free
individuals.1,11,12 At 12 months, surviving AVERT partic-
ipants had a mean AQoL-4D score of 0.53, marginally
higher than the mean of 0.47 reported at 2 years poststroke
in the population-based NEMESIS study.29 When partic-
ipants were stratified by age decade, 2 patterns were no-
table. First, our stroke survivors had median 12-month
AQoL-4D scores >0.13 lower than population norms—
reflecting a clinically meaningful difference in QOL30—
across every decade (excepting the very small sample
of participants under 30). Second, the difference tended to
increase with age: there is a gradual decline in QOL with
age in the norms, but there is a marked decline with age in
the AVERT participants. This may reflect the tendency for
older participants to have more severe strokes, and thus
poorer QOL. Mindful of the strong influence of disability
level, we investigated whether a similar decline in QOL
with age was present in participants with minor stroke-
related symptoms. Among participants who experienced
minor symptoms (mRS 1 or 2) at 12 months, the gap in
QOL to population norms appeared to decrease, rather
than increase, with age. In other words, there was some
evidence that mild deficits had a greater effect on QOL in
younger than in older stroke survivors.
A number of the associations we identified were confirma-
tory: better QOL was related to greater independence
in activities of daily living, having fewer symptoms of de-
pression and anxiety, and living at home rather than in an
institution. There is precedent for our findings of higher
QOL in those with better cognitive function9 and those
who have returned to work.31 In line with previous re-
search,32 we failed to detect a significant difference in QOL
between ischemic and hemorrhagic stroke survivors. Other
findings were more novel. Better QOL was associated
with a shorter length of stay in the acute hospital, and this
may be partly attributable to complications experienced
during the inpatient stay. Analysis of participants by region
indicated that QOL was lower in the United Kingdom than
it was in Australia/New Zealand or Asia. There does not
appear to be a matching difference in QOL between the
general populations of these countries. While no normative
data for the AQoL-4D are available from the United
Kingdom, a national comparison of population norms on
a different scale revealed slightly higher QOL in the United
Kingdom than in New Zealand.33 Data on educational
background revealed that participants with higher levels of
education had better QOL. There is some evidence that
this association is mediated by lower levels of emotional
and physical distress in the better educated, largely brought
about by higher personal control over employment and
economic resources.34 Whatever the explanation un-
derlying these associations (or lack thereof), they cannot be
attributed to simple confounding, as all analyses were ad-
justed for age, sex, and stroke severity.
Our major limitation was missing data, due to deaths and to
other reasons. This is inevitable, given the inclusion of
participants across the full stroke severity spectrum. The
rate of missing data, however, was very low when compared
to that of other poststroke QOL studies,35 and is a tribute
to the work ethic of the blinded assessors. Fewer than 5% of
all participants were excluded from analysis of AQoL-4D
at 12 months due to refusing follow-up, being lost to
follow-up, or having missing data. To minimize missing
data, we allowed for proxy respondents, though we ac-
knowledge that proxies have a tendency to overestimate
impairments and underestimate QOL.36 In our sample, it is
unsurprising that AQoL-4D scores for participants with
proxy respondents were very low, given that these partic-
ipants often had severe stroke or communication problems,
or both.
Our findings indicate that providing early and more frequent
mobilization after stroke does not have a marked influence on
QOL over the subsequent year.
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